NO20062885L - Terapeufiske anti-IGFR1-antistoffkombinasjoner - Google Patents
Terapeufiske anti-IGFR1-antistoffkombinasjonerInfo
- Publication number
- NO20062885L NO20062885L NO20062885A NO20062885A NO20062885L NO 20062885 L NO20062885 L NO 20062885L NO 20062885 A NO20062885 A NO 20062885A NO 20062885 A NO20062885 A NO 20062885A NO 20062885 L NO20062885 L NO 20062885L
- Authority
- NO
- Norway
- Prior art keywords
- therapeutic anti
- antibody combinations
- igfr1 antibody
- combinations
- igfr1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer kombinasjoner som omfatter en bindende sammensetning, f.eks. et anfi-IGFR1-antistoff, sammen med et kjemoterapeutisk middel. Fremgangsmåter for anvendelse av kombinasjonene for behandling av medisinske tilstander, feks. kreft, tilveiebringes også.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52473203P | 2003-11-21 | 2003-11-21 | |
PCT/US2004/038842 WO2005052005A1 (en) | 2003-11-21 | 2004-11-19 | Anti-igfr1 antibody therapeutic combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062885L true NO20062885L (no) | 2006-08-18 |
Family
ID=34632927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062885A NO20062885L (no) | 2003-11-21 | 2006-06-20 | Terapeufiske anti-IGFR1-antistoffkombinasjoner |
Country Status (21)
Country | Link |
---|---|
US (1) | US8017735B2 (no) |
EP (2) | EP2230254B1 (no) |
JP (2) | JP2007532478A (no) |
KR (1) | KR20060100432A (no) |
CN (1) | CN1906214B (no) |
AR (1) | AR046639A1 (no) |
AT (1) | ATE465180T1 (no) |
AU (2) | AU2004292554B2 (no) |
CA (1) | CA2546664A1 (no) |
DE (1) | DE602004026768D1 (no) |
ES (1) | ES2343328T3 (no) |
HK (1) | HK1087131A1 (no) |
IL (1) | IL175773A0 (no) |
NO (1) | NO20062885L (no) |
NZ (1) | NZ547266A (no) |
PE (1) | PE20050928A1 (no) |
PL (1) | PL380527A1 (no) |
SG (1) | SG160412A1 (no) |
TW (1) | TW200526684A (no) |
WO (1) | WO2005052005A1 (no) |
ZA (1) | ZA200604074B (no) |
Families Citing this family (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ554740A (en) * | 2002-05-24 | 2009-01-31 | Schering Corp | Neutralizing human anti-IGFR antibody |
EP1539228B1 (en) | 2002-09-11 | 2010-12-29 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
EP2365001A3 (en) * | 2003-05-01 | 2012-03-28 | Imclone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
EP1694850B1 (en) | 2003-11-12 | 2011-06-29 | Schering Corporation | Plasmid system for multigene expression |
AU2005230818B2 (en) | 2004-04-02 | 2010-11-25 | Osi Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
CA2589885A1 (en) | 2004-12-03 | 2006-06-08 | Schering Corporation | Biomarkers for pre-selection of patients for anti-igf1r therapy |
MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
EP1835905A2 (en) * | 2004-12-31 | 2007-09-26 | Aventis Pharmaceuticals, Inc. | Use of selected compounds for protection of neurones and oligodendrocytes in the treatment of multiple sclerosis |
US10603314B2 (en) | 2005-02-03 | 2020-03-31 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
BRPI0608777A2 (pt) * | 2005-04-15 | 2010-01-26 | Schering Corp | métodos para tratamento ou prevenção de cáncer, bem como uso de inibidores de igf1r na preparação de composições farmacêuticas |
US20060286103A1 (en) * | 2005-06-15 | 2006-12-21 | Parag Kolhe | Stable antibody formulation |
WO2006138729A2 (en) | 2005-06-17 | 2006-12-28 | Imclone Systems Incorporated | Receptor antagonists for treatment of metastatic bone cancer |
FR2888850B1 (fr) * | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
EP1926996B1 (en) | 2005-09-20 | 2011-11-09 | OSI Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20070093449A1 (en) * | 2005-10-14 | 2007-04-26 | De Porre Peter M R | Novel IV formulation of tipifarnib |
AR057854A1 (es) * | 2005-11-04 | 2007-12-19 | Wyeth Corp | Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
EA017265B1 (ru) * | 2006-02-03 | 2012-11-30 | Имклоун Элэлси | Применение антитела imc-a12, которое является ингибитором igf-ir, для лечения рака предстательной железы |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
JP5399900B2 (ja) * | 2006-06-30 | 2014-01-29 | メルク・シャープ・アンド・ドーム・コーポレーション | Igfbp2インヒビター |
WO2008076257A2 (en) * | 2006-12-13 | 2008-06-26 | Schering Corporation | Treating cancer with anti-igflr antibody 19d12 = sch 717454 |
WO2008108986A2 (en) * | 2007-03-02 | 2008-09-12 | Amgen Inc. | Methods and compositions for treating tumor diseases |
JP2010532758A (ja) * | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 組み合わせ抗癌療法 |
AU2008293425B2 (en) * | 2007-08-31 | 2014-09-18 | Amgen Inc. | Solid-state protein formulation |
CA2701032C (en) | 2007-09-27 | 2021-01-26 | Amgen Inc. | Pharmaceutical formulations |
CA2694356A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US7939272B2 (en) | 2007-10-03 | 2011-05-10 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
WO2009091939A1 (en) * | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
EP2259797A2 (en) * | 2008-03-25 | 2010-12-15 | Schering Corporation | Methods for treating or preventing colorectal cancer |
KR101924831B1 (ko) | 2008-04-09 | 2018-12-05 | 제넨테크, 인크. | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 |
MX2010012064A (es) * | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
PT2310011E (pt) | 2008-06-17 | 2013-10-07 | Wyeth Llc | Combinações antineoplásicas contendo hki-272 e vinorelbina |
LT2326329T (lt) | 2008-08-04 | 2017-05-25 | Wyeth Llc | 4-anilin-3-cianochinolinų ir kapecitabino antinavikiniai deriniai |
WO2010054264A1 (en) * | 2008-11-07 | 2010-05-14 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US20110171124A1 (en) * | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2236139A1 (en) | 2009-03-31 | 2010-10-06 | F. Hoffmann-La Roche AG | Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor |
AU2010234968B2 (en) | 2009-04-06 | 2015-05-14 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer |
MX2011011025A (es) | 2009-04-20 | 2011-11-02 | Osi Pharmaceuticals Llc | Preparacion de c-piracin-metilaminas. |
US20120282654A1 (en) * | 2009-04-29 | 2012-11-08 | Schering Corporation | Antibody purification |
WO2010129740A1 (en) * | 2009-05-07 | 2010-11-11 | Osi Pharmaceuticals, Inc. | Use of osi-906 for treating adrenocortical carcinoma |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
US8609675B2 (en) | 2009-07-02 | 2013-12-17 | Merck Sharp & Dohme Corp. | Fused Tricyclic Compounds as novel mTOR inhibitors |
EP2473041B1 (en) | 2009-09-04 | 2018-03-07 | Merck Sharp & Dohme Corp. | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
MX344382B (es) | 2009-10-23 | 2016-12-14 | Amgen Inc * | Adaptador de vial y sistema. |
US20110275644A1 (en) | 2010-03-03 | 2011-11-10 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20110217309A1 (en) * | 2010-03-03 | 2011-09-08 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
HUE026173T2 (en) | 2010-06-07 | 2016-05-30 | Amgen Inc | pharmaceutical Pump |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
US20130323197A1 (en) * | 2010-10-07 | 2013-12-05 | University Of Louisville Research Foundation, Inc. | Ifg-1 dependent modulation of vsels |
AU2012212075A1 (en) | 2011-02-02 | 2013-07-18 | Amgen Inc. | Methods and compositons relating to inhibition of IGF-1R |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
CA2831100C (en) | 2011-03-31 | 2020-02-18 | Mark Dominis Holt | Vial adapter and system |
WO2012145685A1 (en) | 2011-04-20 | 2012-10-26 | Amgen Inc. | Autoinjector apparatus |
JP2014514321A (ja) | 2011-04-21 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | インスリン様増殖因子1受容体阻害剤 |
US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2013016164A1 (en) | 2011-07-26 | 2013-01-31 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS |
EP3335747B1 (en) | 2011-10-14 | 2021-04-07 | Amgen Inc. | Injector and method of assembly |
ES2723827T3 (es) | 2011-11-11 | 2019-09-02 | Univ Duke | Terapia de combinación de fármacos para el tratamiento de tumores sólidos |
EP2631653A1 (en) | 2012-02-24 | 2013-08-28 | Charité - Universitätsmedizin Berlin | Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
WO2014066330A1 (en) * | 2012-10-22 | 2014-05-01 | Georgetown University | Compositions and methods for treating mammary tumors |
EP3656426B1 (en) | 2012-11-21 | 2023-05-17 | Amgen Inc. | Drug delivery device |
CA2941010A1 (en) | 2013-02-26 | 2014-09-04 | Triact Therapeutics, Inc. | Cancer therapy |
ES2973257T3 (es) | 2013-03-15 | 2024-06-19 | Amgen Inc | Casete de fármaco, autoinyector y sistema de autoinyector |
WO2014143815A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
CA2897825C (en) | 2013-03-22 | 2022-05-24 | Scott R. Gibson | Injector and method of assembly |
KR20160030936A (ko) | 2013-07-16 | 2016-03-21 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법 |
US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
WO2015061389A1 (en) | 2013-10-24 | 2015-04-30 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
EP3421066B1 (en) | 2013-10-24 | 2021-03-03 | Amgen Inc. | Injector and method of assembly |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
CA2945026C (en) | 2014-05-07 | 2023-10-10 | Amgen Inc. | Autoinjector with shock reducing elements |
AU2015271767B2 (en) | 2014-06-03 | 2020-04-02 | Amgen Inc. | Controllable drug delivery system and method of use |
EP3206739B1 (en) | 2014-10-14 | 2021-12-01 | Amgen Inc. | Drug injection device with visual and audio indicators |
JP2017538512A (ja) | 2014-12-19 | 2017-12-28 | アムジエン・インコーポレーテツド | ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置 |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
CA3069716C (en) | 2015-02-17 | 2021-11-09 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
EP3261690B1 (en) | 2015-02-27 | 2021-12-15 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
CN108137691B (zh) | 2015-09-02 | 2021-10-19 | 耶路撒冷希伯来大学伊萨姆研究发展有限公司 | 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体 |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
KR20230125094A (ko) | 2015-09-25 | 2023-08-28 | 제넨테크, 인크. | 항-tigit 항체 및 이의 이용 방법 |
US11351308B2 (en) | 2015-12-09 | 2022-06-07 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
EP3429663B1 (en) | 2016-03-15 | 2020-07-15 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
CA3018426A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
EP3478342A1 (en) | 2016-07-01 | 2019-05-08 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
JP2020503976A (ja) | 2017-01-17 | 2020-02-06 | アムジエン・インコーポレーテツド | 注入デバイスならびに関連する使用および組立方法 |
JP7280189B2 (ja) | 2017-02-17 | 2023-05-23 | アムジエン・インコーポレーテツド | 薬物送達装置用の挿入機構 |
CA3048520A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
MX2019010544A (es) | 2017-03-06 | 2019-10-21 | Amgen Inc | Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion. |
KR102627069B1 (ko) | 2017-03-07 | 2024-01-18 | 암겐 인코포레이티드 | 과압에 의한 바늘 삽입 |
JP2020509837A (ja) | 2017-03-09 | 2020-04-02 | アムジエン・インコーポレーテツド | 薬剤送達装置のための挿入機構 |
US11957883B2 (en) | 2017-03-28 | 2024-04-16 | Amgen Inc. | Plunger rod and syringe assembly system and method |
JP7200134B2 (ja) | 2017-06-08 | 2023-01-06 | アムジエン・インコーポレーテツド | トルク駆動式薬物送達デバイス |
CA3061982A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
WO2018236619A1 (en) | 2017-06-22 | 2018-12-27 | Amgen Inc. | REDUCING THE IMPACTS / IMPACTS OF ACTIVATION OF A DEVICE |
AU2018290302B2 (en) | 2017-06-23 | 2024-02-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
MA49562A (fr) | 2017-07-14 | 2020-05-20 | Amgen Inc | Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion |
IL271173B2 (en) | 2017-07-21 | 2024-04-01 | Amgen Inc | Gas permeable sealing element for drug container and methods of assembly |
MA49676A (fr) | 2017-07-25 | 2020-06-03 | Amgen Inc | Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé |
EP3658203B1 (en) | 2017-07-25 | 2022-08-31 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
WO2019032482A2 (en) | 2017-08-09 | 2019-02-14 | Amgen Inc. | HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM |
US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
WO2019046600A1 (en) | 2017-08-30 | 2019-03-07 | Amgen Inc. | INSULIN-RELATED GROWTH FACTOR 1 RECEPTOR BINDING PROTEINS (IGF-1R) AND METHODS OF USE |
ES2939292T3 (es) | 2017-10-04 | 2023-04-20 | Amgen Inc | Adaptador de flujo para dispositivo de administración de fármacos |
MA50614A (fr) | 2017-10-06 | 2020-08-12 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé |
WO2019074579A1 (en) | 2017-10-09 | 2019-04-18 | Amgen Inc. | DRUG DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY AND ASSEMBLY METHOD THEREOF |
MA50528A (fr) | 2017-11-03 | 2020-09-09 | Amgen Inc | Systèmes et approches pour stériliser un dispositif d'administration de médicament |
US20200261648A1 (en) | 2017-11-06 | 2020-08-20 | Amgen Inc. | Drug delivery device with placement and flow sensing |
US20200338271A1 (en) | 2017-11-06 | 2020-10-29 | Amgen Inc. | Fill-finish assemblies and related methods |
CA3079665A1 (en) | 2017-11-10 | 2019-05-16 | Amgen Inc. | Plungers for drug delivery devices |
CN111278487B (zh) | 2017-11-16 | 2022-06-24 | 安进公司 | 用于药物递送装置的门闩锁机构 |
CA3084486A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Autoinjector with stall and end point detection |
WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020023451A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
CA3103681A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
CA3103105A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
US20210346601A1 (en) | 2018-09-24 | 2021-11-11 | Amgen Inc. | Interventional dosing systems and methods |
AU2019350660A1 (en) | 2018-09-28 | 2021-03-18 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
AR116679A1 (es) | 2018-10-02 | 2021-06-02 | Amgen Inc | Sistemas de inyección para la administración de fármacos con transmisión de fuerza interna |
US20210338936A1 (en) | 2018-10-05 | 2021-11-04 | Amgen Inc. | Drug delivery device having dose indicator |
CN112689523A (zh) | 2018-10-15 | 2021-04-20 | 安进公司 | 用于药物递送装置的平台组装方法 |
AU2019361919A1 (en) | 2018-10-15 | 2021-03-18 | Amgen Inc. | Drug delivery device having damping mechanism |
EP3873566A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
CA3113076A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
AU2019372141A1 (en) * | 2018-11-01 | 2021-05-27 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
WO2020172002A1 (en) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Therapeutic antibody formulation |
CA3137360A1 (en) | 2019-04-24 | 2020-10-29 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
CA3148261A1 (en) | 2019-08-23 | 2021-03-04 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
US20230310436A1 (en) * | 2019-10-09 | 2023-10-05 | Cothera Bioscience, Inc. | Combination therapy for cancers with kras mutation |
JP2023545520A (ja) | 2020-10-14 | 2023-10-30 | ビリジアン セラピューティクス, インコーポレイテッド | 甲状腺眼疾患を治療するための組成物及び方法 |
CN114920841B (zh) * | 2021-02-11 | 2023-06-09 | 兰州大学第二医院 | 抗cd87抗体及其特异性嵌合抗原受体 |
KR20240011135A (ko) | 2021-05-21 | 2024-01-25 | 암젠 인크 | 약물 용기를 위한 충전 레시피를 최적화하는 방법 |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
CA2076975A1 (en) | 1990-02-28 | 1991-08-29 | Kevin W. Moore | Mammalian expression vectors |
ATE158615T1 (de) | 1990-03-20 | 1997-10-15 | Univ Columbia | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5198340A (en) | 1991-01-17 | 1993-03-30 | Genentech, Inc. | Assay for free igf-i, igf-ii, and gh levels in body fluids |
WO1993012808A1 (en) * | 1991-12-20 | 1993-07-08 | Shuji Nakamura | A method for treating kaposi's sarcoma and blocking or inhibiting vascular permeability |
US5262308A (en) | 1992-01-28 | 1993-11-16 | Thomas Jefferson University | Cell lines which constitutively express IGF-1 and IGF-1 R |
WO1994002178A1 (en) | 1992-07-27 | 1994-02-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting of liposomes to the blood-brain barrier |
JPH08508409A (ja) | 1993-04-06 | 1996-09-10 | シーダーズ − サイナイ メディカル センター | 変異インスリン様増殖因子▲i▼受容体サブユニットおよびそれらの使用方法 |
US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US20020022023A1 (en) | 1999-01-15 | 2002-02-21 | Axel Ullrich | Treatment of diabetes mellitus and insulin receptor signal transduction |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
WO1997018241A1 (en) | 1995-11-14 | 1997-05-22 | Thomas Jefferson University | Inducing resistance to tumor growth with soluble igf-1 receptor |
US6346390B1 (en) | 1996-03-08 | 2002-02-12 | Receptron, Inc. | Receptor derived peptides involved in modulation of response to ligand binding |
US5958872A (en) | 1996-04-01 | 1999-09-28 | Apoptosis Technology, Inc. | Active survival domains of IGF-IR and methods of use |
US20020169116A1 (en) | 1996-05-22 | 2002-11-14 | Kingston David J. | Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof |
AUPN999096A0 (en) | 1996-05-22 | 1996-06-13 | Northstar Biologicals Pty Ltd | Peptides, antibodies, vaccines & uses thereof |
ZA979295B (en) | 1996-10-18 | 1998-04-20 | Canji Inc | Methods and compositions for delivery and expression of interferon-Ó nucleic acids. |
US20020155095A1 (en) | 1996-10-18 | 2002-10-24 | Tattanahalli L. Nagabhushan | Methods and compositions for delivery and expression of interferon-a nucleic acids |
WO1998022092A1 (en) | 1996-11-22 | 1998-05-28 | The Regents Of The University Of California | Transport of liposomes across the blood-brain barrier |
US6294330B1 (en) | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
DE19719001C2 (de) | 1997-05-06 | 2001-05-10 | Schuetzdeller Angelika | Verfahren zum immunologisch-funktionalen Nachweis biologisch aktiver Insulin-Like Growth Factor Binding Proteine oder löslicher Insulin-Like Growth Factor - Rezeptoren im Immunoassay |
IL136113A0 (en) | 1997-11-14 | 2001-05-20 | Euro Celtique Sa | Modified antibodies with enhanced ability to elicit an anti-idiotype response |
ATE328903T1 (de) | 1997-11-27 | 2006-06-15 | Commw Scient Ind Res Org | Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462) |
AU2783099A (en) | 1998-02-24 | 1999-09-06 | Receptron, Inc. | Receptor derived peptides as modulators of receptor activity |
ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
AU4079999A (en) | 1998-05-15 | 1999-12-06 | Imclone Systems Incorporated | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
US6875741B2 (en) | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
US7173005B2 (en) | 1998-09-02 | 2007-02-06 | Antyra Inc. | Insulin and IGF-1 receptor agonists and antagonists |
US20030236190A1 (en) | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
JP2002527066A (ja) | 1998-10-15 | 2002-08-27 | カイロン コーポレイション | 転移性乳癌および結腸癌調節遺伝子 |
WO2000050067A1 (en) | 1999-02-26 | 2000-08-31 | Saltech I Göteborg Ab | Method and composition for the regulation of hepatic and extrahepatic production of insulin-like growth factor-1 |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
WO2000069454A1 (en) | 1999-05-17 | 2000-11-23 | Board Of Regents, The University Of Texas System | Suppression of endogenous igfbp-2 to inhibit cancer |
AU6607100A (en) | 1999-07-23 | 2001-02-13 | Regents Of The University Of California, The | Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery |
WO2001030964A2 (en) | 1999-10-22 | 2001-05-03 | Lifespan Biosciences, Inc. | Anti-cancer nucleic acid and protein targets |
WO2001044464A1 (en) | 1999-12-15 | 2001-06-21 | Mcgill University | Targeting of endosomal growth factor processing as anti-cancer therapy |
GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
WO2001070930A2 (en) | 2000-03-21 | 2001-09-27 | University Of South Florida | Growth factor binding molecules |
AU2001249393A1 (en) | 2000-03-22 | 2001-10-03 | Glaxo Group Limited | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
WO2001075064A2 (en) | 2000-03-31 | 2001-10-11 | Hyseq, Inc. | Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides |
US6372250B1 (en) | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
GB0012233D0 (en) | 2000-05-19 | 2000-07-12 | Devgen Nv | Vector constructs |
US20030165502A1 (en) | 2000-06-13 | 2003-09-04 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
US7329745B2 (en) | 2000-06-13 | 2008-02-12 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
US20020164333A1 (en) | 2000-07-10 | 2002-11-07 | The Scripps Research Institute | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
AU2001277531A1 (en) | 2000-07-10 | 2002-01-21 | Novartis Ag | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
US20030162230A1 (en) | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
US8153121B2 (en) | 2000-10-06 | 2012-04-10 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders |
MXPA03003207A (es) | 2000-10-12 | 2004-03-26 | Icos Corp | Materiales y metodos para modular la actividad de union de ligando/enzimatica de proteinas alfa/¦ que contienen un sitio regulador alosterico. |
US7344829B2 (en) | 2000-11-03 | 2008-03-18 | Board Of Regents, The University Of Texas System | Methods for detecting the efficacy of anticancer treatments |
WO2002043758A2 (en) | 2000-12-01 | 2002-06-06 | Schering Corporation | Uses of mammalian genes and related reagents |
UY27087A1 (es) | 2001-01-05 | 2002-06-20 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2002074969A2 (en) | 2001-01-26 | 2002-09-26 | University Of Lausanne | Matrix attachment regions and methods for use thereof |
EP1401476A4 (en) | 2001-03-14 | 2006-03-08 | Genentech Inc | IGF ANTAGONIST PEPTIDES |
US20040116330A1 (en) | 2001-04-27 | 2004-06-17 | Kenichiro Naito | Preventive/therapeutic method for cancer |
WO2002100326A2 (en) | 2001-05-01 | 2002-12-19 | The General Hospital Corporation | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
JP2005500034A (ja) | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
AUPR870501A0 (en) | 2001-11-07 | 2001-11-29 | Biotech Research Ventures Pte Limited | Composition containing a flavonoid glycone and method for using same as anti-proliferative |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
ES2427964T3 (es) | 2002-01-18 | 2013-11-05 | Pierre Fabre Medicament | Nuevos anticuerpos anti-IGF-IR y sus aplicaciones |
US7553485B2 (en) | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
FR2834991B1 (fr) | 2002-01-18 | 2004-12-31 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
FR2834900B1 (fr) | 2002-01-18 | 2005-07-01 | Pf Medicament | Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications |
FR2834990A1 (fr) | 2002-01-18 | 2003-07-25 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
WO2003088910A2 (en) | 2002-04-15 | 2003-10-30 | Rigel Pharmaceuticals, Inc. | Methods of assaying for cell cycle modulators |
US7655397B2 (en) | 2002-04-25 | 2010-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers |
US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
NZ554740A (en) * | 2002-05-24 | 2009-01-31 | Schering Corp | Neutralizing human anti-IGFR antibody |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
AU2003249054A1 (en) | 2002-07-12 | 2004-02-02 | The Johns Hopkins University | Neuronal gene expression patterns |
US20040142381A1 (en) | 2002-07-31 | 2004-07-22 | Hubbard Stevan R. | Methods for designing IGF1 receptor modulators for therapeutics |
US20040047835A1 (en) | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
US20030138430A1 (en) | 2002-09-20 | 2003-07-24 | Stimmel Julie Beth | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
ES2383014T3 (es) | 2003-04-02 | 2012-06-15 | F. Hoffmann-La Roche Ag | Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
EP2365001A3 (en) | 2003-05-01 | 2012-03-28 | Imclone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
AU2004251602B2 (en) * | 2003-05-23 | 2010-05-13 | Nektar Therapeutics | PEG derivatives having an amidocarbonate linkage |
AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
EP1660477B1 (en) | 2003-08-07 | 2008-12-10 | Schering Corporation | Novel farnesyl protein transferase inhibitors as antitumor agents |
MXPA06001634A (es) | 2003-08-13 | 2006-04-28 | Pfizer Prod Inc | Anticuerpos humanos modificados igf-1r. |
EP1694850B1 (en) | 2003-11-12 | 2011-06-29 | Schering Corporation | Plasmid system for multigene expression |
CA2564538A1 (en) | 2004-04-22 | 2005-12-01 | Oregon Health And Science University | Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors |
NZ579482A (en) * | 2004-06-01 | 2011-02-25 | Genentech Inc | Antibody drug conjugates and methods |
WO2005117980A1 (en) | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
CN101014365B (zh) | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤 |
US20060205810A1 (en) | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
CA2589885A1 (en) | 2004-12-03 | 2006-06-08 | Schering Corporation | Biomarkers for pre-selection of patients for anti-igf1r therapy |
BRPI0608777A2 (pt) | 2005-04-15 | 2010-01-26 | Schering Corp | métodos para tratamento ou prevenção de cáncer, bem como uso de inibidores de igf1r na preparação de composições farmacêuticas |
US20060286103A1 (en) | 2005-06-15 | 2006-12-21 | Parag Kolhe | Stable antibody formulation |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007093008A1 (en) | 2006-02-17 | 2007-08-23 | Adelaide Research & Innovation Pty Ltd | Antibodies to insulin-like growth factor i receptor |
JP5399900B2 (ja) | 2006-06-30 | 2014-01-29 | メルク・シャープ・アンド・ドーム・コーポレーション | Igfbp2インヒビター |
-
2004
- 2004-11-18 PE PE2004001131A patent/PE20050928A1/es not_active Application Discontinuation
- 2004-11-18 AR ARP040104263A patent/AR046639A1/es unknown
- 2004-11-18 TW TW093135439A patent/TW200526684A/zh unknown
- 2004-11-19 US US10/993,395 patent/US8017735B2/en not_active Expired - Fee Related
- 2004-11-19 WO PCT/US2004/038842 patent/WO2005052005A1/en active Application Filing
- 2004-11-19 EP EP10160260.5A patent/EP2230254B1/en active Active
- 2004-11-19 CN CN2004800408015A patent/CN1906214B/zh not_active Expired - Fee Related
- 2004-11-19 NZ NZ547266A patent/NZ547266A/en not_active IP Right Cessation
- 2004-11-19 AU AU2004292554A patent/AU2004292554B2/en not_active Ceased
- 2004-11-19 DE DE602004026768T patent/DE602004026768D1/de active Active
- 2004-11-19 PL PL380527A patent/PL380527A1/pl unknown
- 2004-11-19 AT AT04811545T patent/ATE465180T1/de not_active IP Right Cessation
- 2004-11-19 JP JP2006541410A patent/JP2007532478A/ja not_active Ceased
- 2004-11-19 SG SG201001853-9A patent/SG160412A1/en unknown
- 2004-11-19 EP EP04811545A patent/EP1689782B1/en active Active
- 2004-11-19 KR KR1020067009791A patent/KR20060100432A/ko active IP Right Grant
- 2004-11-19 ES ES04811545T patent/ES2343328T3/es active Active
- 2004-11-19 CA CA002546664A patent/CA2546664A1/en not_active Abandoned
-
2006
- 2006-05-18 IL IL175773A patent/IL175773A0/en unknown
- 2006-05-19 ZA ZA200604074A patent/ZA200604074B/xx unknown
- 2006-06-20 NO NO20062885A patent/NO20062885L/no not_active Application Discontinuation
- 2006-08-19 HK HK06109205.6A patent/HK1087131A1/xx not_active IP Right Cessation
-
2009
- 2009-08-28 AU AU2009212853A patent/AU2009212853A1/en not_active Abandoned
-
2011
- 2011-08-26 JP JP2011185153A patent/JP2011236253A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1689782B1 (en) | 2010-04-21 |
EP2230254B1 (en) | 2013-05-15 |
JP2007532478A (ja) | 2007-11-15 |
PL380527A1 (pl) | 2007-02-19 |
US8017735B2 (en) | 2011-09-13 |
PE20050928A1 (es) | 2005-11-08 |
DE602004026768D1 (de) | 2010-06-02 |
AR046639A1 (es) | 2005-12-14 |
SG160412A1 (en) | 2010-04-29 |
JP2011236253A (ja) | 2011-11-24 |
CN1906214B (zh) | 2012-06-20 |
ES2343328T3 (es) | 2010-07-28 |
EP2230254A3 (en) | 2010-10-27 |
CA2546664A1 (en) | 2005-06-09 |
HK1087131A1 (en) | 2006-10-06 |
AU2004292554A1 (en) | 2005-06-09 |
WO2005052005A1 (en) | 2005-06-09 |
EP1689782A1 (en) | 2006-08-16 |
KR20060100432A (ko) | 2006-09-20 |
IL175773A0 (en) | 2006-09-05 |
EP2230254A2 (en) | 2010-09-22 |
TW200526684A (en) | 2005-08-16 |
ATE465180T1 (de) | 2010-05-15 |
US20050136063A1 (en) | 2005-06-23 |
AU2009212853A1 (en) | 2009-09-24 |
ZA200604074B (en) | 2007-03-28 |
AU2004292554B2 (en) | 2009-05-28 |
CN1906214A (zh) | 2007-01-31 |
NZ547266A (en) | 2009-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062885L (no) | Terapeufiske anti-IGFR1-antistoffkombinasjoner | |
EA200700225A1 (ru) | Аналоги тетрапептида | |
EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
SE0301700D0 (sv) | Novel compounds | |
ATE408601T1 (de) | Fredericamycin-derivate | |
CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
WO2003080582A3 (de) | Fredericamycin-derivate | |
TW200528117A (en) | Methods and reagents for the treatment of proliferative diseases | |
TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
UY29283A1 (es) | Anticuerpos ab(beta)usados en mejorar la cognicion | |
EA200601555A1 (ru) | Замещенные индазол-о-глюкозиды | |
NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
EA200601554A1 (ru) | Замещенные индол-о-глюкозиды | |
DK1446012T3 (da) | Bakteriolytisk kombinationsterapi til behandling af tumorer | |
DK2054418T3 (da) | Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer | |
BRPI0515721A (pt) | uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação | |
EA200301142A1 (ru) | Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6 | |
WO2005085188A3 (en) | Compounds and methods for anti-tumor therapy | |
ATE542796T1 (de) | N-sulfonylcarboximidamidverbindungen als apoptosepromotoren | |
ATE405568T1 (de) | Cytotoxische mittel | |
EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
WO2005007123A3 (en) | Pin1-modulating compounds and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |